96.88 0.00 (0.00%)
After hours: 5:57PM EST
|Bid||84.50 x 900|
|Ask||99.49 x 1000|
|Day's range||96.77 - 98.72|
|52-week range||59.17 - 100.43|
|Beta (3Y monthly)||0.93|
|PE ratio (TTM)||11.21|
|Earnings date||22 Oct 2018 - 26 Oct 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||92.93|
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Express Scripts' (ESRX) Q3 results hurt by year-over-year decline in adjusted network claims, thanks to the loss of certain public sector clients.
Investing.com - Express Scripts (NASDAQ:ESRX) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.
Express Scripts (ESRX) delivered earnings and revenue surprises of 0.41% and 2.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The St. Louis-based company said it had profit of $1.89 per share. Earnings, adjusted for one-time gains and costs, came to $2.43 per share. The results beat Wall Street expectations. The average estimate ...
Investing.com - U.S. futures rose on Wednesday, with the Dow on track for triple digit gains as corporate earnings results came in higher than expected. The S&P 500 futures rose 22 points or 0.83% to 2,707.0 as of 7:58 AM ET (11:58 GMT) while Dow futures were up 180 points, or 0.72%, to 25,039.0. Meanwhile tech heavy Nasdaq 100 futures increased 84 points, or 1.24%, to 6,900.25.Earnings season remains in focus with results from Kellogg Company (NYSE:K), AIG (NYSE:AIG), Express Scripts (NASDAQ:ESRX) and others. General Motors (NYSE:GM) surged 9. ...
Stocks rose sharply on Wednesday, the last trading day of the month, as strong earnings from General Motors and Facebook lifted sentiment. But the major averages were still on pace for sharp October losses.
Healthcare stocks should gain from increase in revenues, higher premiums and enrollment partly offset by increase in expenses.
Biotech giant Amgen is lowering the price of its cholesterol medicine Repatha by almost 60 percent, following a similar move from its competitor, after both drugs failed to meet sales expectations.
Express Scripts (ESRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Express Scripts (ESRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stock of The Day: Cigna battled doubters for months over its $67 billion Express Scripts takeover. Now, as the deal is almost done, Cigna stock is near a buy point.
CVS CEO Larry Merlo outlined his vision for the combined company earlier this month — a new data-driven health-care model that's more personal, convenient and tailored to individual patients than ever before.
Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.
IBD Stock Of The Day: Centene has a new buy point after rallying from an April breakout. Managed care stocks have been winners in 2018, and are holding up well now.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(IONS), announced today that they are working together with Accredo® specialty pharmacy, a subsidiary of Express Scripts (ESRX), to distribute TEGSEDI™ (inotersen) subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Approved by the U.S. Food and Drug Administration (FDA) today, TEGSEDI is the first and only subcutaneous RNA-targeting therapeutic offering patients an effective treatment for the polyneuropathy of hATTR amyloidosis.